Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Finished Goods (2016 - 2018)

Amicus Therapeutics filings provide 3 years of Finished Goods readings, the most recent being $865000.0 for Q1 2018.

  • On a quarterly basis, Finished Goods rose 284.44% to $865000.0 in Q1 2018 year-over-year; TTM through Mar 2018 was $865000.0, a 284.44% increase, with the full-year FY2017 number at $780000.0, up 622.22% from a year prior.
  • Finished Goods hit $865000.0 in Q1 2018 for Amicus Therapeutics, up from $780000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $865000.0 in Q1 2018 to a low of $57000.0 in Q2 2016.
  • Median Finished Goods over the past 3 years was $207500.0 (2017), compared with a mean of $337500.0.
  • The widest YoY moves for Finished Goods: up 622.22% in 2017, down 139.29% in 2017.
  • Amicus Therapeutics' Finished Goods stood at $108000.0 in 2016, then soared by 622.22% to $780000.0 in 2017, then increased by 10.9% to $865000.0 in 2018.
  • The last three reported values for Finished Goods were $865000.0 (Q1 2018), $780000.0 (Q4 2017), and $335000.0 (Q3 2017) per Business Quant data.